Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / ASMB - Hookipa: Speculative Biotech With Key Catalysts In 2022

ASMB - Hookipa: Speculative Biotech With Key Catalysts In 2022

Assembly Biosciences Inc.
  • Several data readouts of HB-200 alone and in combination with KEYTRUDA for treatment of HPV16+ HNSCC patients are expected in 2022.
  • An amended agreement with Gilead Sciences, for arenavirus platform to develop treatments for HIV and HBV, established $54 million in commitment cash.
  • An IND-filing of HB-300 for the treatment of patients with prostate cancer is expected in Q3 of 2022.
  • HB-700 is another drug in the pipeline which is being advanced to treat several KRAS Mutated cancers such as: colorectal, pancreatic and lung cancers.

For further details see:

Hookipa: Speculative Biotech With Key Catalysts In 2022
Stock Information
Company Name: Assembly Biosciences Inc.
Stock Symbol: ASMB
Market: NASDAQ
Website: assemblybio.com
Menu
ASMB ASMB Quote ASMB Short ASMB News ASMB Articles ASMB Message Board
Get ASMB Alerts

News, Short Squeeze, Breakout and More Instantly...